Premium
In search of novel protein drug targets for treatment of Enterococcus faecalis infections
Author(s) -
Singh Harpreet,
Das Satyajeet,
Yadav Jyoti,
Srivastava Vijay Kumar,
Jyoti Anupam,
Kaushik Sanket
Publication year - 2019
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.13582
Subject(s) - enterococcus faecalis , drug , drug design , drug resistance , antibiotics , multiple drug resistance , rational design , computational biology , bacteremia , medicine , microbiology and biotechnology , biology , bioinformatics , pharmacology , gene , escherichia coli , biochemistry , genetics
Abstract Enterococcus faecalis ( Ef ) is one of the major pathogens involved in hospital‐acquired infections. It can cause nosocomial bacteremia, surgical wound infection, and urinary tract infection. It is important to mention here that Ef is developing resistance against many commonly occurring antibiotics. The occurrence of multidrug resistance ( MDR ) and extensive‐drug resistance ( XDR ) is now posing a major challenge to the medical community. In this regard, to combat the infections caused by Ef , we have to look for an alternative. Rational structure‐based drug design exploits the three‐dimensional structure of the target protein, which can be unraveled by various techniques such as X‐ray crystallography or nuclear magnetic resonance ( NMR ) spectroscopy. In this review, we have discussed the complete picture of Ef infections, the possible treatment available at present, and the alternative treatment options to be explored. This study will help in better understanding of novel biological targets against Ef and the compounds, which are likely to bind with these targets. Using these detailed structural informations, rational structure‐based drug design is achievable and tight inhibitors against Ef can be prepared.